Study of a potential drug delivery system based on carbon nanoparticles: Effects of fullerene derivatives in MCF7 mammary carcinoma cells

Journal of Nanoparticle Research

Volumn 14, Issue 4, 2012, Pages

  Lucafò, Marianna ^a   Pacor, Sabrina ^a   Fabbro, Chiara ^a   Da Ros, Tatiana ^a   Zorzet, Sonia ^a   Prato, Maurizio ^a   Sava, Gianni ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Anticancer drug delivery; Cellular uptake; Cytotoxicity; Fullerene; Nanomedicine; Nanoparticle

Indexed keywords

CELL CULTURE; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; DIAGNOSIS; FLOW CYTOMETRY; FULLERENES; MAMMALS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; TARGETED DRUG DELIVERY; TUMORS;

1 ,3-DIPOLARCYCLOADDITION; ANTI-CANCER DRUG DELIVERY; CARBON NANO-PARTICLES; CELLULAR UPTAKE; FULLERENE DERIVATIVE; INTRACELLULAR DISTRIBUTION; MAMMARY CARCINOMA CELL; STRONG INTERACTION;

CELLS;

CARBON NANOPARTICLE; DOXORUBICIN; FULLERENE DERIVATIVE; NANOPARTICLE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL NUCLEUS; CELL STRAIN MCF 7; CELL VIABILITY; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYCLOADDITION; CYTOPLASM; CYTOTOXICITY; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SECRETORY GRANULE;

EID: 84858726098     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-012-0830-8     Document Type: Article

References (33)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398 (Pubitemid 29222564)
2. Bosi S, Da Ros T, Spalluto G, Prato M (2003) Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem 38 (11-12):913-923 (Pubitemid 37455402)
3. Chaudhuri P, Harfouche R, Soni S, Hentschel DM, Sengupta S (2009a) Shape effect of carbon nanovectors on angiogen-esis. ACS Nano 4 (1):574-582
4. Chaudhuri P, Paraskar A, Soni S, Mashelkar RA, Sengupta S (2009b) Fullerenol cytotoxic conjugates for cancer chemotherapy. ACS Nano 3 (9):2505-2514
5. Debbage P (2009) Targeted drugs and nanomedicine: present and future. Curr Pharm Des 15 (2):153-172
6. Dellinger A et al (2010) Uptake and distribution of fullerenes in human mast cells. Nanomedicine 6:575-581
7. Duncan R, Izzo L (2005) Dendrimer biocompatibility and tox-icity. Adv Drug Deliv Rev 14 57 (15):2215-2237
8. Duvvuri M, Krise JP (2005) Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front Biosci 10:1499-1509 (Pubitemid 40529015)
9. Foley S, Crowley C, Smaihi M, Bonfils C, Erlanger BF, Seta P, Larroque C (2002) Cellular localization of a water-soluble fullerene derivative. Biochem Biophys Res Commun 294 (1):116-119 (Pubitemid 34687223)
10. Gorczyca W (1999) Cytometric analyses to distinguish death processes. Endocr Relat Cancer 6:17-19 (Pubitemid 29197222)
11. Gotink K, Broxterman HJ, Labots M, De Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17 (23):7337-7346
12. Guldi DM, Maggini M, Scorrano G, Prato M (1997) Intramolecular electron transfer in fullerene/ferrocene based donor-bridge-acceptor dyads. J Am Chem Soc 119:974-980 (Pubitemid 27107220)
13. Iyer AK, Khaled G, Fang J, Maeda H (2006) Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11:812-818 (Pubitemid 44280021)
14. Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, Hall MD (2009) Imaging the function of P-glycopro-tein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86 (4):368-377
15. Kessel D, Wilberding C (1984) Mode of action of calcium antagonists which alter anthracycline resistance. Biochem Pharmacol 33 (7):1157-1160 (Pubitemid 14129049)
16. Kordatos K, Da Ros T, Bosi S, Vazquez E, Bergamin M, Cusan C, Pellarini F, Tomberli V, Baiti B, Pantarotto D, Georg-akilas V, Spalluto G, Prato M (2001) Novel versatile ful-lerene synthons. J Org Chem 66:4915-4920
17. 60. Chem Phys 293:263-280
18. Kurtoglu YE, Navath RS, Wang B, Kannan S, Romero R, Kannan RM (2009) Poly (amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. Biomaterials 30:2112-2121
19. Levi N, Hantgan RR, Lively MO, Carroll DL, Prasad GL (2006) C60-fullerenes: detection of intracellular photolumines-cence and lack of cytotoxic effects. J Nanobiotechnol 4 (4):14
20. Lu F, Haque ASK, Yang ST, Luo PG, Gu L, Kitaygorodskiy A, Li H, Lacher S, Sun YP (2009) Aqueous compatible fullerene-doxorubicin conjugates. J Phys Chem 113:17768-17773
21. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolec-ular therapeutics: a review. J Control Release 65:271-284 (Pubitemid 30122932)
22. Maggini M, Prato M (1998) Fulleropyrrolidines: a family of full-fledged fullerene derivatives. Acc Chem Res 31 (9): 519-526 (Pubitemid 128473644)
23. Maggini M, Scorrano G, Prato M (1993) Addition of azomethine ylides to C60: synthesis, characterization and functionali-zation of fullerene- pyrrolidines. J Am Chem Soc 115: 9798-9799
24. Matsumura Y, Maeda H (1986) A new concept for macromo-lecular therapies in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392 (Pubitemid 17221789)
25. Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future prospects. FASEB J 19:311-330 (Pubitemid 40316520)
26. Monteiro-Riviere NA, Inman AO, Zhang LW (2009) Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl Pharmacol 234:222-235
27. Partha R, Conyers JL (2009) Biomedical applications of func-tionalized fullerene-based nanomaterials. Int J Nanomed 4:261-275
28. Partha R, Mitchell LR, Lyon J, Joshi PP, Conyers JL (2008) Buckysomes: fullerene-based nanocarriers for hydropho-bic molecule delivery. ACS Nano 2 (9):1950-1958
29. Surendiran A, Sandhiya S, Pradhan SC, Adithan C (2009) Novel application of nanotechnology in medicine. Indian J Med Res 130:689-701
30. Tattersall M, Clarke S (2003) Developments in drug delivery: implications for cancer care. Curr Opin Oncol 15:293-299 (Pubitemid 36994033)
31. Vail SA, Krawczuk PJ, Guldi DM, Palkar A, Echegoyen L, Tomé JPC, Fazio MA, Schuster DI (2005) Energy and electron transfer in polyacetylene-linked zinc-porphyrin-[60]fullerene molecular wires. Chem Eur J 11:3375-3388 (Pubitemid 40750995)
32. Worle-Knirsch JM, Pulskamp K, Krug HF (2006) Oops they did it again! carbon nanotubes hoax scientists in viability assays. Nano Lett 6:1261-1268 (Pubitemid 44013492)
33. Zhanga LW, Yang J, Barron AR, Monteiro-Riviere NA (2009) Endocytic mechanisms and toxicity of a fullerene in human cells. Toxicol Lett 191:149-157